Cellectis (ALCLS) Stock Overview
A clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ALCLS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Cellectis S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €3.70 |
| 52 Week High | €4.84 |
| 52 Week Low | €1.23 |
| Beta | 2.71 |
| 1 Month Change | 17.46% |
| 3 Month Change | 2.49% |
| 1 Year Change | 160.93% |
| 3 Year Change | 98.18% |
| 5 Year Change | -76.86% |
| Change since IPO | -74.93% |
Recent News & Updates
Recent updates
Lacklustre Performance Is Driving Cellectis S.A.'s (EPA:ALCLS) 26% Price Drop
Nov 08
Subdued Growth No Barrier To Cellectis S.A. (EPA:ALCLS) With Shares Advancing 26%
Sep 23Cellectis S.A. (EPA:ALCLS) Stock Catapults 30% Though Its Price And Business Still Lag The Industry
Jul 15It's Unlikely That Cellectis S.A.'s (EPA:ALCLS) CEO Will See A Huge Pay Rise This Year
Jun 20Need To Know: The Consensus Just Cut Its Cellectis S.A. (EPA:ALCLS) Estimates For 2025
May 17Improved Revenues Required Before Cellectis S.A. (EPA:ALCLS) Stock's 32% Jump Looks Justified
May 04Is Cellectis (EPA:ALCLS) Using Debt In A Risky Way?
Jan 01A Look At The Intrinsic Value Of Cellectis S.A. (EPA:ALCLS)
Feb 07Analyst Forecasts Just Became More Bearish On Cellectis S.A. (EPA:ALCLS)
Aug 09Is Cellectis (EPA:ALCLS) Using Too Much Debt?
Dec 14Analysts' Revenue Estimates For Cellectis S.A. (EPA:ALCLS) Are Surging Higher
Aug 07Shareholder Returns
| ALCLS | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 19.2% | 2.6% | 3.0% |
| 1Y | 160.9% | 349.9% | 7.5% |
Return vs Industry: ALCLS underperformed the French Biotechs industry which returned 367.7% over the past year.
Return vs Market: ALCLS exceeded the French Market which returned 8% over the past year.
Price Volatility
| ALCLS volatility | |
|---|---|
| ALCLS Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 9.0% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in FR Market | 10.2% |
| 10% least volatile stocks in FR Market | 3.0% |
Stable Share Price: ALCLS's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALCLS's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 227 | Andre Choulika | www.cellectis.com |
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC).
Cellectis S.A. Fundamentals Summary
| ALCLS fundamental statistics | |
|---|---|
| Market cap | €268.59m |
| Earnings (TTM) | -€57.47m |
| Revenue (TTM) | €67.68m |
Is ALCLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALCLS income statement (TTM) | |
|---|---|
| Revenue | US$79.59m |
| Cost of Revenue | US$0 |
| Gross Profit | US$79.59m |
| Other Expenses | US$147.19m |
| Earnings | -US$67.59m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.93 |
| Gross Margin | 100.00% |
| Net Profit Margin | -84.92% |
| Debt/Equity Ratio | 67.5% |
How did ALCLS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/13 17:05 |
| End of Day Share Price | 2026/04/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cellectis S.A. is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| Jack Allen | Baird |
| Amanda Murphy | BTIG |